# Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

> **NCT00003472** · PHASE2 · TERMINATED · sponsor: **Burzynski Research Institute** · enrollment: 13 (actual)

## Conditions studied

- Oligodendroglioma, Adult

## Interventions

- **DRUG:** Antineoplaston therapy (Atengenal + Astugenal)

## Key facts

- **NCT ID:** NCT00003472
- **Lead sponsor:** Burzynski Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1996-05
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2018-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003472, "Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*